TABLE 4.
Item | Treatment |
SEM |
P-value |
|||||
CON | RES | LPS | RES + LPS | LPS | RES | LPS × RES | ||
Total protein (g/L) | 31.83 | 32.53 | 29.17 | 32.13 | 1.98 | 0.305 | 0.226 | 0.441 |
Urea acid (μmol/L) | 156.33 | 139.67 | 215.33 | 286.00 | 34.40 | 0.062 | 0.372 | 0.801 |
Glucose (mmol/L) | 13.10 | 13.17 | 12.06 | 12.27 | 1.12 | 0.258 | 0.868 | 0.935 |
Triglyceride (mmol/L) | 0.35b | 0.34b | 0.44a | 0.40ab | 0.03 | 0.003* | 0.246 | 0.480 |
Cholesterol (mmol/L) | 4.22 | 3.92 | 4.63 | 4.22 | 0.33 | 0.072 | 0.382 | 0.738 |
HDL-C (mmol/L) | 2.70b | 2.66b | 3.25a | 2.83b | 0.16 | 0.015* | 0.076 | 0.147 |
LDL-C (mmol/L) | 0.86 | 0.73 | 0.91 | 0.91 | 0.13 | 0.240 | 0.493 | 0.472 |
NEFA (mmol/L) | 0.76 | 0.96 | 1.01 | 0.77 | 0.14 | 0.777 | 0.808 | 0.038* |
AST (U/L) | 171.0ab | 162.2b | 185.2a | 177.2ab | 7.15 | 0.011* | 0.116 | 0.938 |
ALT (U/L) | 1.25 | 1.00 | 1.50 | 1.25 | 0.32 | 0.295 | 0.295 | 1.000 |
Total bile acids (umol/L) | 4.16b | 3.64b | 7.28a | 5.74ab | 1.60 | 0.015* | 0.301 | 0.604 |
Creatine kinase (U/L) | 1073.33ab | 906.33b | 1299.67a | 1130.67ab | 114.96 | 0.024* | 0.073 | 0.990 |
Creatine kinase-MB (U/L) | 1285.27a | 962.30b | 1426.00a | 1321.33a | 70.81 | 0.001* | 0.003* | 0.061 |
Creatinine (μmol/L) | 11.20b | 9.00b | 17.20a | 11.60b | 2.57 | 0.031* | 0.048* | 0.364 |
T3 (ng/mL) | 1.55a | 1.82a | 0.96b | 1.41ab | 0.20 | 0.008* | 0.040* | 0.577 |
T4 (ng/mL) | 46.79ab | 51.70a | 39.86b | 43.94ab | 3.47 | 0.017* | 0.104 | 0.869 |
Insulin (μIU/mL) | 6.35ab | 7.86a | 5.00b | 6.16ab | 0.69 | 0.014* | 0.025* | 0.731 |
Cortisol (ng/mL) | 3.87ab | 1.57a | 7.35b | 3.89ab | 1.66 | 0.038* | 0.039* | 0.631 |
1Values are means and standard error of the means (n = 5).
abMeans in the same row with different superscripts differ (P < 0.05).
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NEFA, none-esterified fatty acid; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CON, control; RES, resveratrol; LPS, lipopolysaccharide; RES + LPS, dietary resveratrol treatment followed by LPS challenge.
The * indicates statistically significant difference (P < 0.05).